Linked Data API

Show Search Form

Search Results

1001918
unstar this property registered interest false more like this
star this property date less than 2018-11-05more like thismore than 2018-11-05
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Rare Diseases: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether officials in his Department have had discussions with the Scottish Government on the (a) Patient and Clinician Engagement system, (b) its effect on approval rates for new rare disease medicines in Scotland and (c) potential lessons from that system for NHS England. more like this
star this property tabling member constituency Bury North more like this
star this property tabling member printed
James Frith more like this
star this property uin 188233 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-11-14more like thismore than 2018-11-14
star this property answer text <p>Officials have had no such discussions. Health is a devolved matter and the availability of medicines for the treatment of rare diseases in Scotland is an issue for the Scottish Government.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-11-14T11:21:33.263Zmore like thismore than 2018-11-14T11:21:33.263Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4637
unstar this property label Biography information for James Frith remove filter
1001919
unstar this property registered interest false more like this
star this property date less than 2018-11-05more like thismore than 2018-11-05
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Rare Diseases: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to paragraph 4.12 the UK Rare Diseases Strategy, what assessment his Department has made of whether the National Institute for Health and Care Excellence’s Single Technology Appraisal Programme meets the ambition of suitability for assessing rare disease treatments. more like this
star this property tabling member constituency Bury North more like this
star this property tabling member printed
James Frith more like this
star this property uin 188234 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-11-12more like thismore than 2018-11-12
star this property answer text <p>Where a company is willing to set a fair price for a drug, the National Institute for Health and Care Excellence (NICE) technology appraisal process has been proven to be suitable for the assessment of drugs for rare diseases. NICE has been able to recommend a number of drugs for patients with rare diseases through its technology appraisal programme; recent examples include dinutuximab beta for neuroblastoma and daratumumab for relapsed and refractory multiple myeloma.</p><p> </p><p>With the aim of improving the lives of all those affected by a rare disease, the United Kingdom Government published the UK Strategy for Rare Diseases in 2013, a high-level framework containing 51 commitments which sets out a seven-year strategic vision (2013-2020). The Government is committed to implementing the Strategy’s commitments and has, in January 2018, published Implementation Plans setting out its actions for England.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-11-12T17:23:30.543Zmore like thismore than 2018-11-12T17:23:30.543Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4637
unstar this property label Biography information for James Frith remove filter
1020384
unstar this property registered interest false more like this
star this property date less than 2018-12-05more like thismore than 2018-12-05
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading NHS: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, when NHS England plans to publish the commercial framework referred to in the policy paper of 5 December 2018 entitled Voluntary scheme for branded medicines pricing and access. more like this
star this property tabling member constituency Bury North more like this
star this property tabling member printed
James Frith more like this
star this property uin 199471 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-12-12more like thismore than 2018-12-12
star this property answer text <p>NHS England, with input from the National Institute for Health and Care Excellence, will develop a ’commercial framework’ setting out the parameters for the commercial approach for medicines in the health service in England. This framework will be tested with and informed through consultation with stakeholders once the voluntary scheme is operational. The intention is to publish the framework early in 2019.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-12-12T15:03:23.873Zmore like thismore than 2018-12-12T15:03:23.873Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4637
unstar this property label Biography information for James Frith remove filter
1023166
unstar this property registered interest false more like this
star this property date less than 2018-12-11more like thismore than 2018-12-11
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Rare Diseases: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 November 2018 to Question 188234 on Rare Diseases: Drugs, whether NICE can make a conditional recommendation for treatment for rare diseases that do not qualify for conditional recommendation through the cancer drugs fund. more like this
star this property tabling member constituency Bury North more like this
star this property tabling member printed
James Frith more like this
star this property uin 201214 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-12-19more like thismore than 2018-12-19
star this property answer text <p>The National Institute of Health and Care Excellence can make a conditional recommendation for treatment for rare diseases that do not qualify for conditional recommendation through the cancer drugs fund. For example, it has recommended the use of belimumab for the treatment of lupus subject to the conditions of a managed access agreement.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-12-19T12:03:22.823Zmore like thismore than 2018-12-19T12:03:22.823Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4637
unstar this property label Biography information for James Frith remove filter
1023167
unstar this property registered interest false more like this
star this property date less than 2018-12-11more like thismore than 2018-12-11
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Rare Diseases: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to his policy paper of 5 December 2018 entitled Voluntary scheme for branded medicines pricing and access, whether NICE plans to review the suitability of its technology appraisal methods for rare disease treatments that do not qualify for the highly specialised technologies programme. more like this
star this property tabling member constituency Bury North more like this
star this property tabling member printed
James Frith more like this
star this property uin 201215 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-12-19more like thismore than 2018-12-19
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is not yet able to advise what will be included in the scope of the review of its technology appraisal methods. NICE will begin scoping the planned review in 2019/20 with the involvement of industry and other relevant stakeholders.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-12-19T12:04:06.617Zmore like thismore than 2018-12-19T12:04:06.617Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4637
unstar this property label Biography information for James Frith remove filter
1028635
unstar this property registered interest false more like this
star this property date less than 2018-12-19more like thismore than 2018-12-19
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Rare Diseases: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 December 2018 to Question 201214 on Rare Diseases: Drugs, on how many occasions NICE has made a conditional recommendation for a rare disease treatment that do not qualify for conditional recommendation through the cancer drugs fund; and what criteria NICE uses to determine whether such treatments are eligible for conditional recommendations. more like this
star this property tabling member constituency Bury North more like this
star this property tabling member printed
James Frith more like this
star this property uin 203975 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-01-07more like thismore than 2019-01-07
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is able to take into account the commercial terms offered by a manufacturer during a NICE appraisal through a mechanism known as a commercial access agreement. On two occasions NICE has issued optimised recommendations to make rare disease medicines routinely available for the appropriate group of National Health Service patients that are conditional on it being supplied in accordance with the terms of the commercial access arrangements. These were Sorafenib, for advanced hepatocellular carcinoma, and ibrutinib for relapsed or refractory mantle cell lymphoma.</p><p> </p><p>This is different from the process of a conditional recommendation for use within the Cancer Drugs Fund (CDF) for oncology drugs, where there is significant remaining clinical uncertainty which needs more investigation through data collection. In these cases funding is provided from the CDF for a time-limited period to allow patient access whilst this data is collected, before guidance is then reviewed again for routine commissioning.</p><p> </p><p>NICE does not have any particular criteria to determine whether treatments are eligible for conditional recommendations. However, the process guide for patient access schemes and commercial access agreements and the CDF can be found at the following link:</p><p><a href="https://www.nice.org.uk/process/pmg19/chapter/patient-access-schemes-commercial-access-agreements-and-flexible-pricing" target="_blank">https://www.nice.org.uk/process/pmg19/chapter/patient-access-schemes-commercial-access-agreements-and-flexible-pricing</a></p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2019-01-07T13:32:56.13Zmore like thismore than 2019-01-07T13:32:56.13Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4637
unstar this property label Biography information for James Frith remove filter
1037139
unstar this property registered interest false more like this
star this property date less than 2019-01-07more like thismore than 2019-01-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Rare Diseases more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the availability of treatments for patients with rare diseases since the introduction of the Orphan Medical Product Regulation 2000. more like this
star this property tabling member constituency Bury North more like this
star this property tabling member printed
James Frith more like this
star this property uin 206027 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-01-15more like thismore than 2019-01-15
star this property answer text <p>The Government is committed to improving the lives of all those affected by a rare disease. Implementation plans by NHS England and the Department were published jointly in January 2018 and describe the actions and framework in place to deliver this commitment to improve the lives of those affected by rare disease, as defined in the UK Strategy for Rare Diseases.</p><p> </p><p>Through its technology appraisal and highly specialised technologies programmes, the National Institute for Health and Care Excellence (NICE) plays an important role in ensuring that patients, including patients with rare diseases, are able to benefit from effective new treatments. NICE has recommended a number of drugs for rare diseases through these programmes that are now routinely funded by the National Health Service for eligible patients.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2019-01-15T16:13:10.783Zmore like thismore than 2019-01-15T16:13:10.783Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4637
unstar this property label Biography information for James Frith remove filter
825489
unstar this property registered interest false more like this
star this property date less than 2018-01-18more like thismore than 2018-01-18
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Dental Services more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how many Units of Dental Activity were delivered in (a) Bury North constituency, (b) Greater Manchester and (c) England in each of the last five years. more like this
star this property tabling member constituency Bury North more like this
star this property tabling member printed
James Frith more like this
star this property uin 123628 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-01-25more like thismore than 2018-01-25
star this property answer text <p>The following table shows the information available on number of units of dental activity delivered for Bury Local Authority, Greater Manchester and England. Data is available for Bury Local Authority, Greater Manchester for 2013/14 to 2016/17 and England for 2012/13 to 2016/17. Data is not available broken down by constituency.</p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Bury Local Authority</p></td><td><p>Greater Manchester<sup>1</sup></p></td><td><p>England</p></td></tr><tr><td><p>2016-17</p></td><td><p>320,578</p></td><td><p>4,952,821</p></td><td><p>85,731,304</p></td></tr><tr><td><p>2015-16</p></td><td><p>337,942</p></td><td><p>4,985,119</p></td><td><p>86,350,897</p></td></tr><tr><td><p>2014-15</p></td><td><p>336,160</p></td><td><p>4,978,641</p></td><td><p>87,220,891</p></td></tr><tr><td><p>2013-14</p></td><td><p>334,639</p></td><td><p>4,985,364</p></td><td><p>88,691,434</p></td></tr><tr><td><p>2012-13</p></td><td><p>-</p></td><td><p>-</p></td><td><p>88,097,804</p></td></tr></tbody></table><p>Source: NHS Digital</p><p> </p><p>Note:</p><p> </p><p><sup>1</sup>Greater Manchester is defined as the following local authorities: Bolton, Bury, Manchester, Oldham, Rochdale, Salford, Stockport, Tameside, Trafford and Wigan.</p><p> </p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-01-25T15:56:01.063Zmore like thismore than 2018-01-25T15:56:01.063Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4637
unstar this property label Biography information for James Frith remove filter
825491
unstar this property registered interest false more like this
star this property date less than 2018-01-18more like thismore than 2018-01-18
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Dentistry: Migrant Workers more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how many overseas qualified dentists are waiting for a Performer Number by country of origin; and what the the average waiting time has been to receive such a number in each of the last three years. more like this
star this property tabling member constituency Bury North more like this
star this property tabling member printed
James Frith more like this
star this property uin 123630 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-01-25more like thismore than 2018-01-25
star this property answer text <p>Information is not held centrally on the number of dentists who qualified overseas who are waiting for a Performer Number or on the average turnaround time for applications to join the National Dental Performers List.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-01-25T13:47:20.947Zmore like thismore than 2018-01-25T13:47:20.947Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4637
unstar this property label Biography information for James Frith remove filter
827972
unstar this property registered interest false more like this
star this property date less than 2018-01-22more like thismore than 2018-01-22
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Dental Services more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how many NHS dental contracts were not completed in each of the last five years; and how many units of dental activity were undelivered in each case. more like this
star this property tabling member constituency Bury North more like this
star this property tabling member printed
James Frith more like this
star this property uin 123932 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-01-30more like thismore than 2018-01-30
star this property answer text <p>This information is not held centrally.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-01-30T14:20:04.347Zmore like thismore than 2018-01-30T14:20:04.347Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4637
unstar this property label Biography information for James Frith remove filter